NASDAQ:KRYS Krystal Biotech Q3 2026 Earnings Report $326.81 -8.04 (-2.40%) Closing price 04:00 PM EasternExtended Trading$329.92 +3.11 (+0.95%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Krystal Biotech EPS ResultsActual EPSN/AConsensus EPS $1.91Beat/MissN/AOne Year Ago EPSN/AKrystal Biotech Revenue ResultsActual RevenueN/AExpected Revenue$129.12 millionBeat/MissN/AYoY Revenue GrowthN/AKrystal Biotech Announcement DetailsQuarterQ3 2026Date11/2/2026TimeBefore Market OpensConference Call DateMonday, November 2, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Krystal Biotech Earnings HeadlinesKrystal Biotech (KRYS) Has a Blockbuster Rare-Disease Drug. Is Its Moat Durable?October 5 at 12:51 AM | insidermonkey.comKrystal Biotech (NASDAQ:KRYS) Research Coverage Started at The Goldman Sachs GroupSeptember 27, 2026 | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 6 at 1:00 AM | Behind the Markets (Ad)Goldman Sachs Resumes Coverage with a Buy Rating on Krystal Biotech (KRYS)September 26, 2026 | theglobeandmail.comBofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy RatingSeptember 21, 2026 | marketscreener.comMKrystal Biotech to Participate in 2026 Cantor Global Healthcare ConferenceSeptember 3, 2026 | quiverquant.comQSee More Krystal Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Krystal Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Krystal Biotech and other key companies, straight to your email. Email Address About Krystal BiotechKrystal Biotech (NASDAQ:KRYS) is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors designed to deliver functional genes to targeted tissues, with the goal of treating diseases caused by genetic mutations. Krystal Biotech’s lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved in the United States for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering. VYJUVEK is designed for repeated application to wounds and became the first commercially available treatment based on the company’s HSV-1 gene-delivery platform. Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech conducts research, clinical development and commercialization activities in the United States and other international markets. The company continues to evaluate its platform for additional rare diseases, including conditions affecting the skin, lungs and other tissues. Krystal Biotech is led by co-founder Krish S. Krishnan, who serves as chairman and chief executive officer.View Krystal Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lamb Weston’s Turnaround Is Starting to Look RealAI Chip Demand Gives Linde a New Growth CatalystInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02 Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
